高级别宫颈不典型增生治疗后的指南一致性监测
该研究回顾性分析了2010至2019年间在两家PROSPR II METRICS站点接受高级别宫颈不典型增生治疗的3146例患者,评估其在治疗后30个月内完成两次阴性联合检测的指南一致性监测情况。结果显示仅45.5%的患者完成了两次监测联合检测,其中约三分之一出现至少一次异常结果,16例(0.5%)诊断为宫颈癌。
要点
- 仅45.5%的患者在治疗后30个月内完成两次指南一致性监测联合检测。
- 完成两次联合检测的患者中约三分之一出现至少一次后续异常联合检测结果。
- 16例(0.5%)患者在治疗后诊断为宫颈癌,中位时间14.9个月。
核心结论
- 约半数患者在接受高级别不典型增生治疗后未获得指南一致性监测,三分之一患者出现后续异常联合检测结果。
- 高级别宫颈不典型增生患者后续异常风险升高,应继续密切监测,需要额外的系统化监测以确保治疗后指南一致性监测。
研究设计与样本
- 回顾性分析2010至2019年在两个PROSPR II METRICS站点(Massachusetts General Brigham、Parkland Health)接受高级别宫颈不典型增生(宫颈上皮内瘤变2级或更严重)治疗的30至65岁患者,共3146例。
- 主要结局为治疗后30个月内(允许6个月排程宽限)获得两次阴性联合检测。
主要发现
- 3146例患者中,Massachusetts General Brigham site 58.9%、Parkland Health site 60.9%为30至39岁;无或较少已知合并症者分别为81.2%和85.6%。
- 仅45.5%的患者在30个月内完成两次监测联合检测(Massachusetts General Brigham 55.3% vs Parkland Health 40.6%)。
- 完成两次联合检测者中,至少一次后续异常联合检测结果的比例为Massachusetts General Brigham 30.9% vs Parkland Health 31.6%。
- 完成两次联合检测者观察时间更长:Massachusetts General Brigham中位64.9个月 vs 33.1个月,Parkland Health中位63.9个月 vs 41.8个月。
- 完成两次联合检测者中,首次联合检测中位时间Massachusetts General Brigham 6.4(5.1-9.2)个月、Parkland Health 10.1(6.6-12.6)个月;两次联合检测间中位时间Massachusetts General Brigham 8.5(6.0-12.6)个月、Parkland Health 12.0(8.0-13.5)个月。
临床怎么用
- 作者认为高级别宫颈不典型增生患者后续异常风险升高,应继续密切监测。
- 作者指出需要额外的系统化监测以确保不典型增生治疗后的指南一致性监测。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To quantify how many patients treated for high-grade cervical dysplasia completed guideline-concordant surveillance. METHODS: We retrospectively analyzed patients aged 30-65 treated for high-grade cervical dysplasia (cervical intraepithelial neoplasia 2 or worse) at two PROSPR II METRICS (Population-based Research to Optimize the Screening Process Multi-level Optimization of the Cervical Cancer Screening Process in Diverse Settings & Populations sites) (Massachusetts General Brigham, Parkland Health) from 2010 to 2019. The primary outcome was receipt of two negative co-tests after treatment within 30 months (allowing 6-month scheduling leeway). RESULTS: Among 3,146 patients treated for high-grade dysplasia, most were aged 30-39 years (Massachusetts General Brigham 58.9%, Parkland Health 60.9%) and had no or few known comorbidities (Massachusetts General Brigham 81.2%, Parkland Health 85.6%). Race and ethnicity, insurance status, and socioeconomic status reflected broader patient population demographics. Only half of the patients (45.5%) completed two surveillance co-tests after treatment within 30 months (Massachusetts General Brigham 55.3%, Parkland Health 40.6%), among whom a third received at least one subsequent abnormal co-test result (Massachusetts General Brigham 30.9%, Parkland Health 31.6%). Patients who completed two co-tests were under observation longer than those who did not complete two co-tests (median Massachusetts General Brigham 64.9 months vs 33.1 months, median Parkland Health 63.9 months vs 41.8 months). Among patients who completed two co-tests, the timing of surveillance co-testing was largely concordant with guidelines (median [interquartile range] time to first co-test: Massachusetts General Brigham 6.4 [5.1-9.2] months, Parkland Health 10.1 [6.6-12.6] months; median [interquartile range] time between first and second co-test: Massachusetts General Brigham 8.5 [6.0-12.6] months, Parkland Health 12.0 [8.0-13.5] months). Overall, 16 patients (0.5%) were diagnosed with cervical cancer after treatment for high-grade dysplasia (median [interquartile range] time from treatment to cancer diagnosis 14.9 [3.8-45.9] months). CONCLUSION: Approximately half of patients did not receive guideline-concordant surveillance after treatment for high-grade dysplasia, and one-third had a subsequent abnormal co-test result. Patients with high-grade cervical dysplasia are at elevated risk of subsequent abnormalities and should continue to be closely monitored. Additional systematic monitoring is needed to ensure guideline-compliant surveillance after dysplasia treatment.
引用
- Wang V, Lykken JM, Tiro JA, et al. Guideline-Concordant Surveillance After Treatment for High-Grade Cervical Dysplasia. Obstet Gynecol. 2025. PMID: 40048731. doi:10.1097/AOG.0000000000005877
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。